-+ 0.00%
-+ 0.00%
-+ 0.00%
SL Science says FDA acknowledges orphan drug designation request for glioblastoma cell therapy
Share
Listen to the news
SL Science says FDA acknowledges orphan drug designation request for glioblastoma cell therapy
  • SL Science submitted an FDA orphan-drug designation request for its Vdelta2+ gamma delta T-cell therapy in glioblastoma.
  • FDA’s Office of Orphan Products Development acknowledged receipt on March 30, 2026, starting its review of additional product files.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SL Science Holding Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607100800PRIMZONEFULLFEED9760089) on July 10, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending